These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
9. Malignant melanoma in Turkey: a single institution's experience on 475 cases. Tas F; Kurul S; Camlica H; Topuz E Jpn J Clin Oncol; 2006 Dec; 36(12):794-9. PubMed ID: 17060409 [TBL] [Abstract][Full Text] [Related]
10. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108 [TBL] [Abstract][Full Text] [Related]
16. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Hsueh EC; Famatiga E; Shu S; Ye X; Morton DL Ann Surg Oncol; 2004 Oct; 11(10):892-9. PubMed ID: 15383418 [TBL] [Abstract][Full Text] [Related]
17. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Morton DL Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194 [TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789 [TBL] [Abstract][Full Text] [Related]
19. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. ; Celis E Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944 [TBL] [Abstract][Full Text] [Related]
20. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Elliott GT; McLeod RA; Perez J; Von Eschen KB Semin Surg Oncol; 1993; 9(3):264-72. PubMed ID: 8516615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]